Back to Trials
NCT07174245Recruiting

Pregnancy and Postpartum CGM in GDM

Icahn School of Medicine at Mount Sinai

Start Date

8/5/2025

Completion Date

7/1/2027

Summary

Gestational diabetes (GDM) is one of the most common complications of pregnancy, and up to one third of women with GDM will have abnormal blood sugars after their pregnancy. To screen for abnormal blood sugars, standard of care is a 4-12 week postpartum oral glucose tolerance test (OGTT). However only 17-60% of women actually have this test performed. This study is to assess continuous glucose monitor data from the third trimester and up to 14 days postpartum to find predictors of postpartum OGTT results.

Detailed Description

Those with GDM in current pregnancy using a Dexcom Continuous Glucose Monitoring (CGM) are eligible for enrollment. Participants use their CGM as usual during pregnancy and wear one sensor postpartum. They have their standard of care OGTT performed at around 6 weeks. They then complete a remote questionnaire after OGTT.

Eligibility Criteria

Age Range: 18 years to No maximum

Inclusion Criteria: * Diagnosis of gestational diabetes during current pregnancy * age 18 or older * prescribed Dexcom G7 Exclusion Criteria: * Pregestational diabetes * known skin adhesive allergy which inhibits ongoing use of CGM * chronic oral steroid use.

Interventions

DEVICE

continuous glucose monitor

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Gestational Diabetes

Locations

Icahn School of Medicine at Mount Sinai

New York, New York 10029

United States